Obiettivo Most cancers remain ‘incurable’ and life-thretening. Cancer stem cells (CSCs) are the source of chemo/radioresistance and responsible for cancer recurrence which suggests the urgent requirement of CSC-targeting drugs. Drug development is a slow (15 years/drug) and costly (US$1.5bn/drug) procedure with only 5-25% of new oncology drugs in clinical development actually reaching the market mainly due to the toxicity of novel molecules. This dilemma has led to an increasing appreciation of the potential of repurposing of known drugs. We have demonstrated that Disulfiram (DS), an old anti-alcoholism drug, possesses excellent anti-CSC activity with low toxicity to normal cells. Whereas its cancer clinial indication is limited by its bio-instability (~4 min half-life in blood stream). Our pilot data demonstrated that the anticancer efficacy of DS is significantly improved when mild extending its half-life by liposome encapsulation. In this study, the Incoming Fellow, who has very strong technical knowhow in cancer research, molecular pharmacology, anticancer drug development and nano-encapsulation, will bring novel nano-biomaterials invented in China into Europe. Taking advantage of the state-of-the-art facilities, CSC models, pharmaceutical resarch and developmental expertise and scientific/technical support from the Incoming Host and the other European collaborators, we will develop a long-circulating nano-encapsulated DS. The anticancer activity of the nano-encapsulated DS will be examined in vitro and in vivo in breast and liver cancer cell lines as well as the relevant CSC models. This study will pave the path for clinical trial of DS in cancer indication. The significance of this project will be: 1. Expand and extend our FP7-IRSES (2011-16) platform to strenthen long-term collaboration between China and EU partners; 2. Develop a new cancer therapeutics for the benefic of healthcare in Europe; 3. Open a new drug developmental window to benefit European economy. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicineoncologyliver cancerengineering and technologynanotechnologymedical and health sciencesmedical biotechnologycells technologiesstem cells Programma(i) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Argomento(i) FP7-PEOPLE-2013-IIF - Marie Curie Action: "International Incoming Fellowships" Invito a presentare proposte FP7-PEOPLE-2013-IIF Vedi altri progetti per questo bando Meccanismo di finanziamento MC-IIF - International Incoming Fellowships (IIF) Coordinatore UNIVERSITY OF WOLVERHAMPTON Contributo UE € 299 558,40 Indirizzo WULFRUNA STREET WV1 1LY Wolverhampton Regno Unito Mostra sulla mappa Regione West Midlands (England) West Midlands Wolverhampton Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Weiguang Wang (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato